Graft Versus Host Disease (GVHD)

Prevention
- BMT304
  Phase II
  Obinutuzumab in Prevention of cGVHD After Allogeneic Peripheral Blood Stem Cell Transplant
  PI: Miklos Dana Farber

- BMT350-EXT
  Extended Treatment & Follow-up of Subjects Treated w/ Belumosudil in Study
  KD025-208 or KD025-213
  PI: Arai Kadmon Corporation, LLC

Chronic
- BMT363
  Early Detection of Bronchiolitis Obliterans Syndrome in Survivors of HCT w/ Handheld Spirometry
  PI: Hsu Fred Hutch

- BMT374
  Phase II
  Axatilimab in Recurrent/ Refractory Active Chronic GVHD Who Have Received >=2 Lines of Systemic Therapy
  PI: Arai Sponsor: Syndax Pharmaceuticals, Inc.

Acute
- BMT344
  Phase III Alpha l-Antitrypsin +/- Corticosteroids in High Risk Acute GVHD After Allogeneic HSCT
  PI: Shiraz Stanford

Diagnostic
- BMT267
  Phase I Primary T Regulatory Cell Tx in Treat Visceral Acute GVHD After HCT
  PI: Meyer Stanford

- BMT323
  Detection of GVHD w/ [18F]-D-AraG, a Positron Emission Tomography Tracer for Activated T Cells
  PI: Gambhir Stanford